News
Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press Release
See all News
Joshua Zelig
DirectorJoshua Zelig joined Burrill & Company as a Director in the Venture Group in 2011. Prior to joining the Company, Mr. Zelig was an Associate Partner at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. In that capacity he was responsible for sourcing, evaluating, and executing investment transactions and new business opportunities. Additionally, Mr. Zelig managed the firm’s intellectual property portfolios, oversaw the company’s operations, and worked closely with portfolio companies in setting and delivering strategic objectives.
Previously, Mr. Zelig was an Equity Research associate at Morgan Stanley where he covered biotech and consumer stocks. He later worked in real estate management, acquisition, and due diligence on behalf of a number of large private real estate companies as well as public REITs.
Mr. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance.


